An Open-label, Single Ascending Dose, Pharmacokinetic and Tolerability Study of NFC-1 in Children and Adolescents (Ages 6-17 Years) With Attention Deficit Hyperactivity Disorder
Phase of Trial: Phase I
Latest Information Update: 31 Mar 2017
At a glance
- Drugs Fasoracetam (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Pharmacokinetics
- Sponsors Aevi Genomic Medicine
- 28 Mar 2017 Status changed from recruiting to completed.
- 06 Mar 2017 Planned End Date changed from 1 Feb 2017 to 1 Mar 2017.
- 06 Mar 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Mar 2017.